Alimta

... FDA Advisory Committee "The Pink Sheet" "The Tan Sheet" Health News Daily Other FDC Pubs.

Pharmaceutical Approvals NDA Pipeline "The Gold Sheet" "The Blue Sheet" "The Gray Sheet" "The Silver Sheet" "The Rose Sheet" MY PREFERENCES CONTACT US Allergenic Products Anesthetic and Life Support Drugs Anti-Infective Drugs Pediatric Subcommittee Antiviral Drugs Immunosuppressive Drugs Arthritis Drugs Blood Products Cardiovascular and Renal Drugs Cellular, Tissue and Gene Therapies Biological Response Modifiers Dermatologic and Ophthalmic Drugs Device Panels Drug Safety and Risk Mgmt Drug Abuse Endocrinologic and Metabolic Drugs Gastrointestinal Drugs Medical Imaging Drugs Nonprescription Drugs Oncologic Drugs Pediatric Pediatric Ethics Subcmte.

Peripheral and Central Nervous System Drugs Pharmaceutical Science Nonclinical Studies Manufacturing Pharmacology/Toxicology Clinical Pharmacology Orally Inhaled & Nasal Drug Products Pharmacy Compounding Psychopharmacologic Drugs Public Meetings Pulmonary-Allergy Drugs Reproductive Health Drugs Science Board Transmissible Spongiform Encephalopathies Vaccines and Related Biological Products A D V E R T I S E M E N T Oncologic Committee To Meet Nov.

8 On Accelerated Approval Commitments FDA will seek advice from its Oncologic Drugs Advisory Committee on how sponsors can better execute studies to complete postmarketing commitments for accelerated approval drugs.

The committee wil...

Read more...